Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZAMBA
2024-517345-14-00Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lumbodynia (LBP) comparing Zoledronic acid (Aclasta) with Placebo (sodium chloride) (2 arms). Primary endpoint: Oswestry Disability Index change at 1 year. Planned start Nov 2025; status: authorised.
02
Drugs
zoledronic acid
03
Conditions
lumbodynia (LBP)
Beyond the preview
Go deeper on 2024-517345-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517345-14-00.